FASN inhibition as a potential treatment for endocrine-resistant breast cancer

Breast Cancer Research and Treatment - The majority of breast cancers are estrogen receptor (ERα) positive making endocrine therapy a mainstay for these patients. Unfortunately, resistance to...     

病理分化程度对声门上型喉癌颈清扫的影响

目的 分析不同分化程度的声门上型喉鳞状细胞癌（SLSCC）的颈淋巴结转移（LNM）规律。方法 回顾性分析2015年1月—2019年12月于重庆医科大学附属第一医院病理诊断为SLSCC的患者不同病理分化程度LNM的差异。结果 共纳入79例患者,其中低分化组20例、中分化组52例和高分化组7例;N0 38例,N1 8例,N2 28例,N3 5例;36例出现Ⅱ区LNM,21例出现Ⅲ区LNM,7例出现Ⅳ区LNM,Ⅴ区和Ⅵ区未发现LNM。结论 SLSCC患者能从双侧颈清扫术中获益,低、中分化患者能从清扫双侧Ⅱ-Ⅳ区中获益,高分化患者清扫双侧Ⅱ-Ⅲ区可能更合适。     

Proportion and extent of manifestation of molar‐incisor‐hypomineralizations according to different phenotypes

Objective: This epidemiological study aimed to assess the proportion and extent of manifestation of enamel hypomineralization, including molar‐incisor‐hypomineralization (MIH), in the permanent and primary dentition. Methods: A total of 693 children enrolled in an ongoing birth cohort study (GINIplus‐10) were examined at their 10‐year follow‐up. Enamel hypomineralization was scored in the primary and permanent dentition on a tooth‐ and surface‐related level based on the criteria of the European Academy of Paediatric Dentistry (EAPD). Children were grouped according to their distribution pattern of enamel hypomineralization: children with a minimum of one hypomineralized tooth in the primary dentition (ht ≥ 1) and permanent dentition (HT ≥ 1); with a minimum of one hypomineralization on at least one first permanent molar (MIH); and with hypomineralization on at least one first permanent molar and permanent incisor (M + IH). For each group, the mean values of hypomineralized primary teeth (ht), permanent teeth (HT), and permanent surfaces (HS) were calculated. Results: The proportion of affected children was 36.5 percent (HT ≥ 1), 14.7 percent (MIH), and 9.4 percent (M + IH); 6.9 percent of the subjects had a minimum of one affected primary tooth (ht ≥ 1). The mean number of hypomineralized permanent teeth and surfaces were 2.3HT/2.9HS (HT ≥ 1), 3.4HT/4.8HS (MIH), and 4.2HT/5.9HS (M + IH). The mean number of hypomineralized primary teeth amounted to 0.1ht in the entire study population. Conclusions: Enamel hypomineralization can be detected frequently in this study sample. Children with M + IH showed the highest number of affected teeth and surfaces followed by those with MIH.     

参附注射液作用机制的计算机系统生物学分析

目的:参附注射液是传统中药红参与附子的复方制剂,临床主适应症为充血性心力衰竭、缺血性脑卒中等。以缺血性脑卒中为导向,采用系统生物学和实验研究方法,对参附注射液调节生物学网络的分子机制做一阐释。方法:以参附注射液的28个成分出发,分别从TCMGene DIT数据库系统和Agilent literature search系统中挖掘参附注射液中成分作用的蛋白质数据,并辅助以Pharmmapper反向对接靶标,构建参附注射液多成分-蛋白网络,在Genecards,BIND,Bio GRID,Int Act,Mint等数据库中挖掘蛋白之间关联,建立蛋白相互作用网络。提取显著性差异蛋白子网络一个,并对其中通路以Western blot蛋白印迹方法加以验证。结果:参附注射液成分与55个蛋白有连接,构成53个无孤立结点的蛋白相互作用网络。应用Cluster One模块对蛋白相互作用网络富集分析,提取显著性差异P0.05的子网络1个,子网络中含有关键蛋白15个,经Biocart信号通路映射,涉及NF-κB信号通路,AKT信号通路,Toll样受体信号通路,MAPK信号通路等。采取Western blot方法对富集指数P值最小的NF-κB信号通路进行验证,发现参附注射液在缺血1 h再灌注24 h的MCAO模型上对NF-κB p65和IκB-α的磷酸化表达有明显下调作用。结论:采用计算机系统生物学和实验验证方式初步阐释了参附注射液主要化合物防治疾病的分子机制,并以分子生物学实验方式对所预测的信号通路进行验证,为中药复方的系统研究提供参考。     

黑逍遥散联合肾四味对乳腺癌大鼠类更年期症状的影响

目的观察黑逍遥散联合肾四味预防他莫昔芬引起的乳腺癌大鼠的类更年期症状的影响。方法60只大鼠腹腔注射MNU溶液,构建大鼠的乳腺癌模型。大鼠随机分为3组:A组(空白对照组)20只,B组(他莫西芬对照组)20只,C组(黑逍遥散联合肾四味组)20只。比较3组大鼠的生存率、行为学评分、体质量、血脂和激素水平的变化。结果经过24周,A组大鼠生存率35.00%(7/20),B组和C组大鼠生存率均为75.00%(15/20)。3组大鼠的生存率有统计学意义(P0.05)。A组和C组大鼠的行为学评分和雌激素、孕激素水平无统计学意义(P0.05),与A、C组大鼠相比,B组大鼠的行为学评分和雌激素、孕激素明显下降(P0.05)。A组和B组大鼠的体质量无统计学意义(P0.05),C组大鼠的体质量明显高于A、B组大鼠(P0.05)。各组大鼠的CHO、TG、HDL-C和LDL-C水平无统计学意义(P0.05)。结论黑逍遥散联合肾四味能有效预防乳腺癌大鼠因应用他莫昔芬导致的类更年期症状,且安全性较高。     

胫骨近端骨折合并腘血管损伤的诊断和治疗

目的:总结胫骨近端骨折合并腘血管损伤的诊断治疗经验。方法:2009年5月-2013年5月期间,我科共收治7例胫骨近端骨折合并腘血管损伤患者,从受伤至血管造影确诊时间为伤后6~25h,平均10.3h,探查见腘动、静脉完全及不完全断裂各3例,腘动、静脉挫伤并栓塞1例,所有病例在确诊后立即手术,行胫骨近端骨折外固定架跨膝关节固定+腘血管探查吻合移植修复治疗。结果:其中6例下肢存有不同程度功能障碍及畸形,1例行截肢术。结论:胫骨近端骨折合并腘血管损伤后,应仔细检查,尽早行血管造影,避免漏诊,明确诊断后应尽快固定骨折,探查吻合血管,最大程度避免截肢等不良后果。     

三白草提取物抗乳腺癌转移作用及其机制研究

目的:研究三白草提取物(extracts from Saururi Herba,ESH)的抗乳腺癌转移作用。方法:采用尾静脉注射肿瘤细胞法建立实验性转移模型;采用体外细胞黏附、迁移以及侵袭法,观察ESH对乳腺癌细胞系MDA-MB-231细胞的体外黏附、迁移以及侵袭的影响;采用Runx2转录因子分析法和Western blot法,观察ESH对Runx2活性的影响。结果:给药后,ESH 200,400 mg·kg-1剂量组裸鼠肺组织中人ck19的平均表达量分别为55.85%,42.28%,显著低于空白组(P0.01);体外黏附实验表明,ESH可干扰肿瘤细胞与细胞外基质蛋白之间的黏附(P0.01);ESH 80,160 g·L-1剂量组的细胞迁移细胞数分别为(106.4±52.4),(40.4±7.6)个,与空白组相比具有统计学差异(P0.01);细胞侵袭实验表明,ESH低、中、高剂量组的侵袭细胞抑制率分别为32.57%,68.04%和71.92%,与空白组相比具有统计学差异(P0.01)。Runx2转录因子活性分析以及Western blot实验结果表明,ESH可显著抑制Runx2的磷酸化,从而抑制其转录活性。结论:ESH具有明显的抗乳腺癌转移作用。抑制细胞内Runx2磷酸化可能是其发挥抗转移作用的机制之一。